Water-soluble polymers conjugated to proteins and anticancer drugs are in routine clinical use and clinical development as both single agents and components of combination therapy. This is ...
The hottest cancer technology from the turn of the century is finally getting its glow-up moment, as clinical trials continue to show that antibody-drug conjugates (ADCs) perform better than standard ...
Practice-changing data in endometrial cancer support checkpoint inhibitor–chemotherapy combinations, extending ...
Please provide your email address to receive an email when new articles are posted on . The most common ocular adverse events with antibody-drug conjugates involve the ocular surface. The mainstay of ...
Following intravenous administration, ADCs circulate in the bloodstream (①) and specifically bind to their target antigen on the tumor cell surface (②). The antigen–ADC complex undergoes ...
In the companion to this article, Krop et al 1 reported the results of the KAITLIN trial, which compared the efficacy, toxicity, and patient-reported outcomes (PRO) of two postoperative therapy ...
Driving Innovation in Discovery and Chemistry, Validating Clinical Proof-of Concept and Streamlining CMC of Conjugates with Novel Payloads and Formats Traditional ADCs have seen significant success in ...
The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...
The global antibody drug conjugates (ADCs) market is poised for steady expansion, projected to grow at a CAGR of approximately 9% over the forecast period. This growth trajectory is deeply influenced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results